Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...

Company closed $22M financing to support randomized Phase 2b trial; IND cleared and study initiated; Interim results anticipated in late 2026; topline data expected in H2/2027 ...

Jazz Pharmaceuticals (NASDAQ:JAZZ) used an investor call following the ASCO Gastrointestinal Cancer Symposium to highlight ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, al ...

China NMPA grants breakthrough therapy designation to Kelun-Biotech’s sacituzumab tirumotecan in combo with immunotherapy pembrolizumab for first-line treatment of PD-L1-positive NSCLC ...

Liv Hospital, the pioneer provider of personalized care, relies on the principle that each patient's cancer is different. The team undertakes to target the specific causes of a person's cancer rather ...

Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

A Potential New Standard for First-Line HER2+ Advanced GEA* Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 status* High GEA burden ...

Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and ...

Rakuten Medical has added to its tally of mega-rounds, pocketing another $100 million to push its lead light-based cancer ...